Bendamustine
Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
Beth ChristianSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bortezomib National Cancer Institute (NCI) | Phase 2 | B |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
Vinorelbine National Cancer Institute (NCI) | Phase 2 | B |
Ifosfamide National Cancer Institute (NCI) | Phase 2 | B |
cc-5013 Ohio State University Comprehensive Cancer Center | Phase 2 | B |
View all 10 →
Same molecule, other indications
Bendamustine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →